COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004-2401 TEL 202 662 6000 FAX 202 662 6291 WWW COV COM WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

April 29, 2005

VIA HAND DELIVERY

Division of Dockets Management Branch U.S. Food and Drug Administration Department of Health & Human Services, rm. 1-23 5630 Fishers Lane, Room 1061 Rockville, MD 20852

PETITION FOR STAY OF ACTION

Docket No. 2003P-0159

The undersigned, on behalf of Wyeth Pharmaceuticals ("Wyeth"), submits this petition requesting that the Commissioner of Food and Drugs stay the effective date of the following action.

A. Decision involved

By letter of March 30, 2005, ¹ FDA approved Lachman Consultant Services, Inc.'s Suitability Petition, submitted April 16, 2003 (2003P-0159(CP1)) (the "Suitability Petition"). FDA's decision permits the filing of an abbreviated new drug application (ANDA) for venlafaxine hydrochloride extended-release tablets, 37.5 mg, 75 mg, and 150 mg. Wyeth has filed a petition for administrative reconsideration to this docket concurrently with this submission (the "Petition for Reconsideration").

B. Action requested

Pursuant to FDA's regulations at 21 C.F.R. § 10.35, the undersigned requests that the Commissioner stay approval of the Suitability Petition until such time as the Commissioner has ruled on Wyeth's Petition for Reconsideration.

2003P-0159

PSA 1

¹ Letter from FDA to Lachman Consultant Services, Inc. (2003P-0159(PAV1)), at 1 (March 30, 2005)

COVINGTON & BURLING

Division of Dockets Management Branch April 29, 2005 Page 2

C. Statement of Grounds

Wyeth bases this Petition for Stay of Action on the grounds set forth in the Petition for Reconsideration.

Respectfully submitted,

Michael S. Labson Scott L. Cunningham

Attorneys for Wyeth Pharmaceuticals

Covington & Burling 1201 Pennsylvania Ave., N.W. Washington, D.C. 20004-2401